Skip to main content
. Author manuscript; available in PMC: 2017 May 3.
Published in final edited form as: Nature. 2016 Sep 5;539(7627):112–117. doi: 10.1038/nature19796

Extended Data Fig. 6. Extended disease control in heavily pretreated patient with metastatic ccRCC with sensitive (XP165) tumorgraft.

Extended Data Fig. 6

CT images of selected lesions in patient treated with highly related HIF-2 inhibitor (PT2385) in phase 1 clinical trial showing overall stability in the size of lesions over time. Start of treatment, day 0.